Bristol Myers Squibb Company $BMY Shares Bought by OVERSEA CHINESE BANKING Corp Ltd

OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 299.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,914 shares of the biopharmaceutical company’s stock after purchasing an additional 15,678 shares during the period. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Bristol Myers Squibb were worth $1,128,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in BMY. Gateway Investment Advisers LLC increased its position in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after acquiring an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC increased its position in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares in the last quarter. Stephens Inc. AR increased its position in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after acquiring an additional 32,476 shares in the last quarter. Railway Pension Investments Ltd increased its position in shares of Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after acquiring an additional 40,300 shares in the last quarter. Finally, Phoenix Financial Ltd. increased its position in shares of Bristol Myers Squibb by 110.1% in the third quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock worth $4,789,000 after acquiring an additional 55,624 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

BMY stock opened at $58.84 on Thursday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a market cap of $120.13 billion, a P/E ratio of 17.05, a P/E/G ratio of 0.17 and a beta of 0.27. The firm has a 50 day simple moving average of $59.74 and a 200 day simple moving average of $53.95. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.28 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Bank of America dropped their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Morgan Stanley restated an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.31.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays upgraded BMY to a Buy, citing reasons that support upside versus peers — a clear near-term catalyst for positive investor flows. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Positive Sentiment: A momentum/long-term interest piece argues BMY is a top momentum stock, which can draw growth-oriented buyers and support multiple expansion if sentiment improves. Why Bristol Myers Squibb (BMY) is a top momentum stock for the long term
• Positive Sentiment: Zacks published bullish commentary framing BMY as a strong value pick vs. peers, highlighting relative valuation and an improving earnings outlook — supportive for value-oriented investors. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Positive Sentiment: Zacks also ran a comparative piece arguing BMY stacks up better than Gilead on valuation and growth potential, which can attract investors rotating within large-cap biopharma. Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
• Neutral Sentiment: Bernstein kept a Hold on BMY; that maintains neutral analyst pressure (no clear push to buy or sell). Investors may wait for further catalyst or clearer conviction. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Geronimo Power’s new Blevins solar project will supply power to two counterparties including Bristol Myers Squibb — a modest ESG / cost-stability positive but unlikely to move the stock materiality. Geronimo Power commences operations at 270MW Blevins Solar Project
• Neutral Sentiment: Two market reports highlight BMY’s involvement in vulvar cancer and Sjögren’s syndrome treatment landscapes — useful pipeline context but not immediate stock-moving clinical data. Vulvar Cancer Market Global and Regional Analysis Report 2025-2035 Sjogren’s Syndrome Market Analysis Report 2025-2035
• Negative Sentiment: A Wall Street roundup flagged downbeat forecasts for select stocks (including BMY in context), which can pressure the stock by amplifying risk-off positioning among institutional desks. 1 Unpopular Stock That Should Get More Attention and 2 We Question

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.